In a November 5, 2013 interview on CNBC, Acorda CEO Ron Cohen announced that the company has filed a regulatory application to the FDA for its diazepam nasal spray for the treatment of epilepsy. Acorda has announced previously that it planned to submit a 505(b)(2) application for the product. Cohen said that if the drug is approved, the drug could be marketed as early as 2014.
The diazepam nasal spray was initially developed by SK Holdings’ life sciences division and licensed to Neuronex in 2010. Neuronex was acquired by Acorda in early 2012.
View the CNBC interview (Cohen begins talking about the product with about 2:50 left in the video)
